HCC-LIVE | Agenda

2027 AGENDA

*Non-accredited Session

Thursday, February 18, 2027

4:00–7:00 PM

Registration

6:30–8:30 PM

Welcome Reception • Exhibit Hall • Poster Viewing*

Friday, February 19, 2027

6:45–8:00 AM

Registration • Breakfast • Poster Viewing*

7:15–8:00 AM

Industry-Sponsored Event*

8:00–8:10 AM

Welcome and Year in Review

Anjana Pillai, MD

Session 1 — Systemic Therapy

Moderator: Nguyen H. Tran, MD

8:10–8:20 AM

New Emerging Therapies: ADCs and Immunotherapeutic Approaches for HCC
(Bispecifics and Novel Targets)

Anthony B. El-Khoueiry, MD

8:20–8:30 AM

Novel Emerging Therapies:

Targeted Approaches for HCC

David Pinato, MD, PhD

8:30–8:40 AM

Next Generation First Line Designs in HCC

Katie Kelley, MD

8:40–8:50 AM Moving

Targeted Therapies to First-Line Treatment in Cholangiocarcinoma

Tanios S. Bekaii-Saab, MD

8:50–9:30 AM

Panel Discussion and Q&A

9:30–10:00 AM

Break • Exhibit Hall • Poster Viewing*

Session 2 — Locoregional Therapy

Moderators: Rich Finn, MD; Kirema Garcia-Reyes, MD

10:00–10:10 AM

Role of SBRT in PVT

Nina Sanford, MD

10:10–10:20 AM

Bridging and Downstaging Beyond the Limits of Locoregional Therapy

Chris Malone, MD

10:20–10:30 AM

TACE in the United States:

Preventing Obsolescence

Julius Chapiro, MD

10:30–10:40 AM

Operationalizing Combination Therapy: How Do We Optimize TARE/Y-90 + IO?

Beau Toskich, MD

10:40–10:50 AM

Critical Evaluation of EMERALD-3

Robert Lewandowski, MD

10:50–11:30 AM

Panel Discussion and Q&A

Session 3 — Surgical Therapy

Moderators: Julie K. Heimbach, MD; Vatche Agopian, MD

11:30–11:40 AM

Transplant Decision-Making in Advanced Age and MASH

Karim J. Halazun, MD

11:40–11:50 AM

Making Sense of Neoadjuvant Therapy Prior to Surgery

Parissa Tabrizian, MD

11:50 AM–12:00 PM

Making Sense of Neoadjuvant Therapy in Intrahepatic Cholangiocarcinoma

Sumera I. Ilyas, MBBS

12:00–12:10 PM

Advances in Robotic Surgery for HCC Jason Solomon Hawksworth, MD

12:10–12:40 PM

Panel Discussion and Q&A

12:40–1:40 PM

Lunch • Exhibit Hall • Poster Viewing*

12:50–1:35 PM

Industry-Sponsored Event*

Session 4 — Surveillance & Biomarkers

Moderator: Amit Singal, MD

1:40–1:50 PM

Abbreviated MRI vs. Blood-Based Biomarkers:

What is the Future of Surveillance?

Neehar Dilip Parikh, MD

1:50–2:00 PM

Radiomics (and/or Pathomics) for HCC Response to Systemic Therapy: What Does It Add to Clinical Factors?

Julius Chapiro, MD, PhD

2:00–2:10 PM

Treatment Selection Biomarkers: Why and How Do They Work for CCA but Not HCC?

James J. Harding, MD

2:10–2:20 PM

Minimal Residual Disease: Is There Clinical Utility?

Vatche Agopian, MD

2:20–3:00 PM

Panel Discussion and Q&A

Oral Presentations — Abstracts

Moderators: Mark Yarchoan, MD; Haley Ellis, MD

3:00–3:10 PM

Oral Abstract #1

ROWAN AND EMERALD-Y90

Riad Salem, MD

3:10–3:20 PM

Oral Abstract #2

TALENTOP

Speaker to be announced

3:20–3:30 PM

Oral Abstract #3

Topics to be announced

Speaker to be announced

Session 5 — Tumor Board: Part 1

Moderators: Anjana Pillai, MD;

Mishal Mendiratta-Lala, MD

3:30–3:45 PM

Case 1

3:45–4:00 PM

Case 2

4:00–4:15 PM

Case 3

4:15–4:20 PM

Day 1 Wrap-Up and Closing Remarks

Anjana Pillai, MD

6:30–8:30 PM

Welcome Reception*

Saturday, February 20, 2027

7:00–8:00 AM

Breakfast • Exhibit Hall • Poster Viewing*

7:00–7:45 AM

Industry-Sponsored Event*

Session 6 — HCC-LIVE Professorship Award

8:00–8:05 AM

Welcome to Day 2

Amit Singal, MD

8:05–8:10 AM

Topic to be announced

Speaker to be announced

8:10–8:30 AM

Distinguished Lecture Series: A Career Story

Riad Salem, MD

Session 7 — Debates

Moderators: Laura M. Kulik, MD; Beau Toskich, MD

8:30–8:50 AM

LRT Has a Role in Advanced Disease (BEACON Class IIIB)

Edward Kim, MD vs. Tanios S. Bekaii-Saab, MD

8:50–9:10 AM

Surgery vs. Neoadjuvant Immunotherapy for High-Risk Disease (Inclusion Criteria for TALENTOP)

Karim J. Halazun, MD vs. David Pinato, MD, PhD

9:10–9:30 AM

TARE is as Curative as Surgical Resection

Kirema I. Garcia-Reyes, MD vs. Adam Yopp, MD

9:30–9:50 AM

LT for Vp3-Vp4 (Favorable Response to IO) in HCC

Neil Mehta, MD vs. Nicole Rich, MD

9:50–10:20 AM

Break • Exhibit Hall • Poster Viewing*

Session 8 — Patient Advocacy

Moderator: To be announced

10:20–10:35 AM

Patient Story: Navigating HCC Diagnosis

Matt Kern

10:35–10:40 AM

Q&A

Session 9 -— Hot Topics

Moderator: Anjana Pillai, MD

10:40–10:50 AM

BEACON HCC

Amit Singal, MD

10:50–11:00 AM

Trial Designs and End Points in HCC

Josep M. Llovet, MD, PhD

11:00–11:10 AM

Mechanisms of Resistance to Immune Checkpoint Blockade in HCC

Tim Greten, MD

11:10–11:20 AM

Intismeran Vaccine: What Does It Mean for Liver Cancer?

Mark Yarchoan, MD

11:20–11:30 AM

Novel Targets for Prevention of MASH-Related HCC

Laura Kulik, MD

11:30 AM–12:20 PM

Panel Discussion

Session 10 -— Tumor Board: Part 2

Moderators: Neil Mehta, MD; Atoosa Rabiie, MD

12:20–12:35 PM

Case 4

12:35–12:50 PM

Case 5

12:50–1:05 PM

Case 6

1:05–1:15 PM

Day 2 Wrap-Up and Closing Remarks

Riad Salem, MD